-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, KZ6VbtO4kwzYutG5X5CjWLO4+B1J6nbazLvf7SoQNNMLAot79yfm99rt6Zbrkykp d02QKlESw61OevIPitEiXQ== 0001238925-07-000005.txt : 20070531 0001238925-07-000005.hdr.sgml : 20070531 20070531182240 ACCESSION NUMBER: 0001238925-07-000005 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20070524 FILED AS OF DATE: 20070531 DATE AS OF CHANGE: 20070531 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOSITE INC CENTRAL INDEX KEY: 0000834306 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 330288606 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 11030 ROSELLE ST CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 6194554808 MAIL ADDRESS: STREET 1: 11030 ROSELLE ST CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: BIOSITE DIAGNOSTICS INC DATE OF NAME CHANGE: 19960710 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: PADILLA NADINE E CENTRAL INDEX KEY: 0001238925 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-21873 FILM NUMBER: 07892040 BUSINESS ADDRESS: STREET 1: C/O BIOSITE INC STREET 2: 11030 ROSELLE STREET CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8584554808 4/A 1 edgardoc.xml PRIMARY DOCUMENT X0202 4/A 2007-05-24 2007-05-24 0 0000834306 BIOSITE INC BSTE 0001238925 PADILLA NADINE E BIOSITE INCORPORATED 9975 SUMMERS RIDGE ROAD SAN DIEGO CA 92121 0 1 0 1 Vice President Corporate & Vice President Corporate & Common Stock 2007-05-24 4 M 0 7251 31.625 A 9947 D Common Stock 2007-05-24 4 S 0 7251 91.7498 D 2696 D Common Stock 2007-05-24 4 M 0 1291 34.375 A 3987 D Common Stock 2007-05-24 4 S 0 1291 91.7498 D 2696 D Common Stock 2007-05-24 4 M 0 3925 34.375 A 6621 D Common Stock 2007-05-24 4 S 0 3925 91.7498 D 2696 D Common Stock 2007-05-24 4 M 0 2182 34.375 A 4878 D Common Stock 2007-05-24 4 S 0 2182 91.7737 D 2696 D Common Stock 2007-05-24 4 M 0 2406 41.56 A 5102 D Common Stock 2007-05-24 4 S 0 2406 91.7737 D 2696 D Common Stock 2007-05-24 4 M 0 27594 41.56 A 30290 D Common Stock 2007-05-24 4 S 0 27594 91.7737 D 2696 D Common Stock 2007-05-24 4 M 0 1596 24.95 A 4292 D Common Stock 2007-05-24 4 S 0 1596 91.7498 D 2696 D Common Stock 2007-05-24 4 M 0 1008 24.95 A 3704 D Common Stock 2007-05-24 4 S 0 1008 91.741 D 2696 D Common Stock 2007-05-24 4 M 0 14496 24.95 A 17192 D Common Stock 2007-05-24 4 S 0 14496 91.741 D 2696 D Common Stock 2007-05-24 4 M 0 2310 44.18 A 5006 D Common Stock 2007-05-24 4 S 0 2310 91.7737 D 2696 D Incentive Stock Option (right to buy) 24.95 2007-05-24 4 M 0 1596 91.7498 D 2002-06-18 2012-06-18 Common Stock 1596 1008 D Incentive Stock Option (right to buy) 24.95 2007-05-24 4 M 0 1008 91.741 D 2002-06-18 2012-06-18 Common Stock 1008 0 D Incentive Stock Option (right to buy) 31.625 2007-05-24 4 M 0 7251 91.7498 D 2000-06-02 2010-06-02 Common Stock 7251 0 D Incentive Stock Option (right to buy) 34.375 2007-05-24 4 M 0 1291 91.7498 D 2000-10-03 2010-10-03 Common Stock 1291 2182 D Incentive Stock Option (right to buy) 34.375 2007-05-24 4 M 0 2182 91.7737 D 2000-10-03 2010-10-03 Common Stock 2182 0 D Incentive Stock Option (right to buy) 41.56 2007-05-24 4 M 0 2406 91.7737 D 2001-06-14 2011-06-14 Common Stock 2406 0 D Non-Qualified Stock Option (right to buy) 24.95 2007-05-24 4 M 0 14496 91.741 D 2002-06-18 2012-06-18 Common Stock 14496 0 D Non-Qualified Stock Option (right to buy) 34.375 2007-05-24 4 M 0 3925 91.7498 D 2000-10-03 2010-10-03 Common Stock 3925 0 D Non-Qualified Stock Option (right to buy) 41.56 2007-05-24 4 M 0 27594 91.7737 D 2001-06-14 2011-06-14 Common Stock 27594 0 D Non-Qualified Stock Option (right to buy) 44.18 2007-05-24 4 M 0 2310 91.7737 D 2004-06-18 2014-06-18 Common Stock 2310 10061 D Option vests daily over a four-year period commencing on the date of grant, except that no options are exercisable for the first six months after the date of grant. The total number of shares sold and subsequent sales prices reported on the reporting persons original Form 4 was incorrect. By: Robyn Shutak For: Nadine Padilla 2007-05-31 -----END PRIVACY-ENHANCED MESSAGE-----